Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.80 |
| ▸ | FLT4 | P35916 | 8/20 | 0.80 |
| ▸ | KDR | P35968 | 7/20 | 0.80 |
| ▸ | KIT | P10721 | 6/20 | 0.80 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.75 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.71 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603444 | 1.00 | FLT3 (0.80) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL13256143 | 0.92 | NTRK1 (0.76) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3599504 | 0.91 | FLT3 (0.77) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3599506 | 0.91 | FLT3 (0.77) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3590032 | 0.89 | FLT3 (0.90) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3590029 | 0.89 | FLT3 (0.90) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3604875 | 0.89 | NTRK1 (0.77) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3604877 | 0.89 | NTRK1 (0.77) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL13256099 | 0.88 | FLT3 (0.71) | FLT3FLT4KDRKITNTRK3 | |
| SCHEMBL3607932 | 0.88 | NTRK1 (0.79) | FLT3FLT4KDRKITNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | claimed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NTRK2, PDGFRB, PDGFRA | FLT3 127/4885FLT4 203/4885KDR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.